News coverage about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) has been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cipher Pharmaceuticals earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9805531237735 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Cipher Pharmaceuticals (NASDAQ CPHR) remained flat at $2.99 on Wednesday. Cipher Pharmaceuticals has a 52-week low of $2.55 and a 52-week high of $4.81. The firm’s 50 day moving average price is $3.05 and its 200-day moving average price is $3.01.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
